논문KCI 등재
Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
2
조회
0
다운로드
0
인용
0
참고문헌
주제분류내과학
참고문헌 (5)
- Sookaromdee Pathum, "Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19", Infection and Chemotherapy, 54(2), pp.369~369 (2022), 대한감염학회[DOI]
- Guo CM, "Fluvoxamine for the early treatment of COVID-19 : A meta-analysis of randomized clinical trials", Am J Trop Med Hyg, 106, pp.1315~1320 (2022)
- Lenze EJ, "Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19 : A randomized clinical trial", JAMA, 324, pp.2292~2300 (2020)
- Reis G, "Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19 : the TOGETHER randomised, platform clinical trial", Lancet Glob Health, 10, pp.e42~51 (2022)
- Seo Hyeonji, "Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial", Infection and Chemotherapy, 54(1), pp.102~113 (2022), 대한감염학회[DOI]
관련 논문AI추천
Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19Sookaromdee Pathum, Wiwanitkit Viroj대한감염학회 · Infection and Chemotherapy2022 · 제54권 제2호Erratum : Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled TrialBae Seongman, Choi Sang-Ho, Chong Yong Pil, Chung Hyemin, Jung Jiwon, Kim Haein, Kim Min-Jae, Kim Sung-Han, Kim Yang Soo, Lee Sang-Oh, Park Seonghee, Seo Hyeonji, Son Ki Young, Sung Heungsup대한감염학회 · Infection and Chemotherapy2022 · 제54권 제2호Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled TrialBae Seongman, Choi Sang-Ho, Chong Yong Pil, Chung Hyemin, Jung Jiwon, Kim Haein, Kim Min-Jae, Kim Sung-Han, Kim Yang Soo, Lee Sang-Oh, Park Seonghee, Seo Hyeonji, Son Ki Young, Sung Heungsup대한감염학회 · Infection and Chemotherapy2022 · 제54권 제1호Reply: Vitamin C as a Possible Therapy for COVID-19Kim Sun Bean, Yeom Joon Sup대한감염학회 · Infection and Chemotherapy2020 · 제52권 제2호Reply: Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated InfectionsAbdullah Jahangir, Syeda Sahra대한감염학회 · Infection and Chemotherapy2021 · 제53권 제3호Reply: Response to Usefulness of the Rapid Antigen Test in Detecting SARS-CoV-2 for Infection Control in HospitalsJung Jiwon, Kim Sung-Han대한감염학회 · Infection and Chemotherapy2024 · 제56권 제2호
이 간행물의 다른 논문 (24건)
Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?Kim Jinyeong, Kim Bongyoung, 김지은, Pai Hyunjoopp. 213-219Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients장현하pp. 220-235Candida auris : An Overview of the Emerging Drug-Resistant Fungal InfectionPrakash Stephanie, Sanyaolu Adekunle, Okorie Chuku, Marinkovic Aleksandra, Abbasi Abu Fahad, Mangat Jasmine, Hosein Zaheeda, Haider Nafees, Chan Jenniferpp. 236-246Expert Consensus on Measures to Promote Physical and Psychological Health among COVID-19-Related Healthcare Workers in Korea using Delphi TechniqueLee Shinwon, Park Kyung-Hwa, 정혜숙, Hong Ki Jeong, Kim Kyoung-Beom, Lee So Hee, Kwon Ki Tae, Kim Yeonjae, Noh Jin-Won, Ryoo Hyun Wook, Heo Sang Taekpp. 247-257Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant OutbreakLee Chan Mi, 박상원, 이은영pp. 258-265